APEIRON Biologics AG, based in Vienna, Austria, is a biotech company with a focus on biological and immunological approaches to treat cancer. The company was founded by Professor Josef Penninger and became operational in 2006. Apeiron currently employs about 35 people and is led by a management team with strong background in drug development, especially in immuno-oncology.


Apeiron's lead project APN311, an antibody-based therapy to treat patients suffering from neuroblastoma (a rare childhood cancer) has completed clinical development and its first application for marketing authorization is under review.
See projects for the present status of Apeiron's portfolio.

 

  • 354 hits28 August 2017

    Investment Plan for Europe: EIB grants financing to Apeiron

    The European Investment Bank (EIB) will provide financing of EUR 25 million to the Austrian biotech company Apeiron Biologics AG (Apeiron). The financing will support the development of new pharmaceutical products to treat cancer, particularly a rare type affecting children. The transaction with Apeiron was made possible by the support of the “European Fund for Strategic Investments” (EFSI). EFSI is the central pillar of the “Investment Plan for Europe”, in which the EIB Group and the European Commission as strategic partners aim to boost the competitiveness of the European economy. (read more...)

     Presseaussendung

     Press Release